David, many here will say that nwbo has buy-in from all the RAs as linda powers did say they would not go to data lock until they had such buy-in. However lp has said many things that have not come to pass including the September 2020 video of tld to be released later that month
More than a year ago ATL kindly shared with us that the European sites had changed their sites to show the new sap. I called and talked with Dave Innes about it and he would not acknowledge the change saying nwbo had nothing to do with that. He would not even acknowledge the change, I commented that I did not think the European site just made it up, it had to come from somewhere. Di just maintained nwbo had nothing to do with it. I then switched to clinicaltrials.gov and he did say that nwbo is the one to update that site and I asked if nwbo had any plans to update and basically got no answer at all. It was not a very fruitful conversation so just wished him well and ended the conversation.
We hope, and many on this board are convinced of buy-in by all but I am still not sure and still have seen no updates on clinicaltrials.gov
We imo do see some positive signs of developments with the fda but imo still is not very clear and certainly not much from the company. Progress at Sawston is a definite positive.
Yesterday just hypothesizing with one of my coinvestors even if we could just get the data out and approval in Europe that would be a huge plus. IF (emphasis on IF) fda is indeed lagging (I hope not) they certainly would eventually follow.
Most/all of the other companies I have been invested in do share more information with shareholders as compared to nwbo. AF does try to twist their information but the companies I have been in just tend to ignore him or in some cases refute the false narrative. It was not AF but look at nvax in late October when an anomous source claimed manufacturing problems, the rumor did drop the stock to 120 (under that premarket) the company refuted the rumor, I picked up a few hundred more shares at what I consider cheap, and now is over 200.
I do agree things can get twisted (especially on message boards) but when companies have good data I believe that wins out in the end.
I had AVNR with a treatment for pseudobulbar affect and AF trashed them every month for at least 2 years. Eventually they had excellent success and were bought out by a private company at a nice premium. At the end AF had a one liner and said 'guess I was wrong on this one'. It has been my experience that companies sharing good data win in the end.
I have learned from multiple examples and don't know of any examples similar to nwbo. Others here I have not seen provide such examples but I admit I do not read all the posts so may have missed such an example. I just hope the article will eventually come out and longs will be rewarded and patients will get a treatment option. Also hope they write a book and tell what really happened behind the scenes for the last 7 years. A few years back the ceo of JAZZ gave a long interview of their struggles and eventual success- I found it very interesting
Good luck
Market Data 
Markets 
AI
